Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cougar Biotechnology, Inc.
Cougar Biotechnology’s Board of Directors Recommends Stockholders Accept Johnson & Johnson’s $43.00 Per Share Cash Tender Offer
June 28th, 2009
Cougar Biotechnology, Inc. (NASDAQ: CGRB) announced that its board of directors has unanimously agreed to recommend that stockholders tender their shares to Johnson & Johnson (NASDAQ: JNJ) at the previously announced price of $43.00 per share. The directors also indicated that they intend to tender all their shares of Cougar Biotechnology. The transaction is expected to close during the third quarter of 2009 and is subject to various conditions, including the tender of at least a majority of the outstanding shares of Cougar common stock in the tender offer and the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. Following...
Source: Pharma Investments, Ventures & Law Weekly (2009-06-28)
|
